Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANF NASDAQ:CMND NASDAQ:CYTO NASDAQ:EVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$1.03+1.0%$1.07$0.98▼$4.69$3.65M1.11241,073 shs54,533 shsCMNDClearmind Medicine$1.04+4.5%$0.95$0.80▼$2.30$4.23M0.93644,588 shs430,813 shsCYTOAltamira Therapeutics$0.30-25.9%$0.36$0.30▼$1.53$1.02M1.8308,898 shs753,013 shsEVAXEvaxion A/S$2.48+7.8%$2.18$1.20▼$17.75$3.23M0.12618,994 shs32,403 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma0.00%-2.86%-6.85%-23.31%-57.85%CMNDClearmind Medicine-10.77%+10.24%+4.57%+3.57%-37.99%CYTOAltamira Therapeutics0.00%0.00%0.00%0.00%-76.56%EVAXEvaxion A/S-4.37%-6.12%-26.52%+66.67%-85.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCANFCan-Fite BioPharma3.2722 of 5 stars3.75.00.00.00.00.01.3CMNDClearmind Medicine0.635 of 5 stars0.03.00.00.02.41.70.0CYTOAltamira TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEVAXEvaxion A/S2.2889 of 5 stars3.55.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANFCan-Fite BioPharma 3.33Buy$14.001,259.22% UpsideCMNDClearmind Medicine 0.00N/AN/AN/ACYTOAltamira Therapeutics 0.00N/AN/AN/AEVAXEvaxion A/S 3.00Buy$10.00303.23% UpsideCurrent Analyst Ratings BreakdownLatest CYTO, CANF, EVAX, and CMND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANFCan-Fite BioPharma$674K5.41N/AN/A$1.76 per share0.59CMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/ACYTOAltamira Therapeutics$320K3.19N/AN/A$4.56 per share0.07EVAXEvaxion A/S$3.34M1.04N/AN/A($1.18) per share-2.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/ACMNDClearmind Medicine-$5.26M-$1.100.00∞N/AN/A-164.79%-71.12%N/ACYTOAltamira Therapeutics-$4.31MN/A0.00N/AN/AN/AN/AN/AN/AEVAXEvaxion A/S-$10.57M-$1.160.00N/AN/A-316.03%-532.72%-78.32%8/13/2025 (Estimated)Latest CYTO, CANF, EVAX, and CMND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/12/2025Q2 2025CMNDClearmind MedicineN/A-$0.16N/A-$0.16N/AN/A5/27/2025Q1 2025EVAXEvaxion A/S-$0.65-$0.29+$0.36-$0.29$0.06 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCANFCan-Fite BioPharmaN/AN/AN/AN/AN/ACMNDClearmind MedicineN/AN/AN/AN/AN/ACYTOAltamira TherapeuticsN/AN/AN/AN/AN/AEVAXEvaxion A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANFCan-Fite BioPharmaN/A2.93N/ACMNDClearmind MedicineN/A1.741.74CYTOAltamira TherapeuticsN/A0.43N/AEVAXEvaxion A/SN/A2.012.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANFCan-Fite BioPharma21.00%CMNDClearmind Medicine96.05%CYTOAltamira Therapeutics1.91%EVAXEvaxion A/S11.04%Insider OwnershipCompanyInsider OwnershipCANFCan-Fite BioPharma0.80%CMNDClearmind MedicineN/ACYTOAltamira Therapeutics13.03%EVAXEvaxion A/S41.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableCYTOAltamira Therapeutics203.40 million2.96 millionNot OptionableEVAXEvaxion A/S601.40 million819,000No DataCYTO, CANF, EVAX, and CMND HeadlinesRecent News About These CompaniesEvaxion CEO Departs; CFO and Interim CEO AppointedJuly 1, 2025 | marketwatch.comEvaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolioJuly 1, 2025 | globenewswire.comEvaxion A/S (NASDAQ:EVAX) Upgraded at Wall Street ZenJune 28, 2025 | americanbankingnews.comEvaxion A/S Launches EVX-B4 Vaccine Development Program Targeting Group A Streptococcus InfectionsJune 27, 2025 | nasdaq.comEvaxion unveils new vaccine program to prevent group A Streptococcus infectionsJune 27, 2025 | bioworld.comBEvaxion A/S (EVAX) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comEVAX AI Technology Produces New Vaccine CandidateJune 25, 2025 | msn.comEvaxion expands R&D pipeline with new vaccine program targeting Group A StreptococcusJune 25, 2025 | globenewswire.comEvaxion Biotech Receives Grant Funding to Develop New Polio VaccineJune 4, 2025 | msn.comEvaxion receives grant funding to design new polio vaccineJune 3, 2025 | globenewswire.comEvaxion Biotech A/S (NASDAQ:EVAX) Q1 2025 Earnings Call TranscriptMay 29, 2025 | msn.comEvaxion Biotech’s Earnings Call Highlights Progress and ChallengesMay 29, 2025 | msn.comEvaxion Biotech Reports Q1 2025 Progress and FinancialsMay 27, 2025 | tipranks.comEvaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call TranscriptMay 27, 2025 | seekingalpha.comEvaxion Biotech: Evaxion announces business update and first quarter 2025 financial resultsMay 27, 2025 | finanznachrichten.deEvaxion announces business update and first quarter 2025 financial resultsMay 27, 2025 | globenewswire.comA Look at Evaxion Biotech's Upcoming Earnings ReportMay 26, 2025 | benzinga.comEvaxion Biotech: Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025May 25, 2025 | finanznachrichten.deEvaxion A/S to Host Conference Call for Q1 2025 Financial Results and Business Update on May 27, 2025May 25, 2025 | nasdaq.comEvaxion at Sidoti Conference: AI-Driven Drug Development StrategyMay 23, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYTO, CANF, EVAX, and CMND Company DescriptionsCan-Fite BioPharma NYSE:CANF$1.03 +0.01 (+0.98%) Closing price 03:55 PM EasternExtended Trading$1.03 +0.00 (+0.49%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Clearmind Medicine NASDAQ:CMND$1.04 +0.04 (+4.47%) Closing price 03:59 PM EasternExtended Trading$0.98 -0.05 (-4.98%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Altamira Therapeutics NASDAQ:CYTOAltamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Evaxion A/S NASDAQ:EVAX$2.48 +0.18 (+7.83%) Closing price 04:00 PM EasternExtended Trading$2.48 0.00 (0.00%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
